Aug. 24 at 10:22 AM
Citizens reiterated
$KURA at Market Outperform-
$24 after Kura recently announced 2Q26 financial results.
$SNDX $BMY AMGN ABBV - RHHBY
Citizens said -- With the KOMZIFTI launch and multiple registrational studies underway, updated ziftomenib combo data expected at ASH, the FTI platform expected to enter registrational studies in 2028, and a cash position of
$519MM, we believe Kura shares represent an attractive investment, with ~57% potential downside (bear case of
$5) and ~156% potential upside (bull case of
$30).
